Normal component of TMS-induced electric field is correlated with depressive symptom relief in treatment-resistant depression

TY - JOUR

T1 - Normal component of TMS-induced electric field is correlated with depressive symptom relief in treatment-resistant depression

AU - Zhang, Bella B.B.

AU - Stöhrmann, Peter

AU - Godbersen, Godber M.

AU - Unterholzner, Jakob

AU - Kasper, Siegfried

AU - Kranz, Georg S.

AU - Lanzenberger, Rupert

N1 - Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: In the past three years S. Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speaker bureaus for Abbott, Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Lundbeck, Recordati, Sage, Sanofi, Schwabe, Servier, Sun Pharma and Vifor. Without any relevance to this work, R. Lanzenberger declares that he received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and Heel, and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. G.S. Kranz declares that he received conference speaker honorarium from Roche, AOP Orphan and Pfizer. J Unterholzner received travel grants from MEDICE Pharma GmbH & Co. KG. The other authors do not report any conflict of interest. Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: In the past three years S. Kasper has received grant/research support from Lundbeck; he has served as a consultant or on advisory boards for Angelini, Biogen, Esai, Janssen, IQVIA, Lundbeck, Mylan, Recordati, Sage and Schwabe; and he has served on speaker bureaus for Abbott, Angelini, Aspen Farmaceutica S.A., Biogen, Janssen, Lundbeck, Recordati, Sage, Sanofi, Schwabe, Servier, Sun Pharma and Vifor. Without any relevance to this work, R. Lanzenberger declares that he received travel grants and/or conference speaker honoraria within the last three years from Bruker BioSpin MR and Heel, and has served as a consultant for Ono Pharmaceutical. He received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. G.S. Kranz declares that he received conference speaker honorarium from Roche, AOP Orphan and Pfizer. J Unterholzner received travel grants from MEDICE Pharma GmbH & Co. KG. The other authors do not report any conflict of interest.This research was supported by the Austrian Science Fund (FWF) [grant number KLI 551, PI: S. Kasper] and the General Research Fund (GRF) under the University Grants Committee (UGC) of the Hong Kong Special Administrative Region [grant numbers 15100120 and 25100219, PI: G.S. Kranz]. B.B.B. Zhang is funded by the Ernst Mach Grant, a scholarship of the OeAD, Austria's Agency for Education and Internationalisation. We would like to thank Richard Frey, Gregor Gryglewski, Marius Hienert, Marie Spies, Christoph Kraus, Alexander Kautzky, Arkadiusz Komorowski, Paul Michenthaler, Pia Baldinger-Melich for clinical support, and Sebastian Ganger, Andreas Hahn and Murray Reed for technical support of the main study. We would further like to thank all participants for their time and effort in participating.

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85139229099&partnerID=8YFLogxK

U2 - 10.1016/j.brs.2022.09.006

DO - 10.1016/j.brs.2022.09.006

M3 - Letter

C2 - 36130678

AN - SCOPUS:85139229099

SN - 1935-861X

VL - 15

SP - 1318

EP - 1320

JO - Brain Stimulation

JF - Brain Stimulation

IS - 5

ER -